- Report
- March 2025
- 250 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- January 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- March 2025
- 150 Pages
Global
From €2911EUR$3,250USD£2,481GBP
€4344EUR$4,850USD£3,703GBP
- Report
- February 2025
- 150 Pages
Global
From €2911EUR$3,250USD£2,481GBP
€4344EUR$4,850USD£3,703GBP
- Report
- November 2024
- 150 Pages
Global
From €2911EUR$3,250USD£2,481GBP
€4344EUR$4,850USD£3,703GBP
- Report
- November 2024
- 150 Pages
Global
From €2911EUR$3,250USD£2,481GBP
€4344EUR$4,850USD£3,703GBP
- Report
- June 2025
- 380 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 172 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 89 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 488 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 72 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 382 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 360 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 181 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 196 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 89 Pages
Global
From €5240EUR$5,850USD£4,467GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more